Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cangrelor plus ticagrelor versus ticagrelor alone during primary PCI in STEMI patients with high platelet reactivity
2020-003621-36Phase 3Completed
- Sponsor
- CHU Caen Normandie
- Start
- Nov 2020
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in myocardial infarction (MI) comparing Cangrelor plus ticagrelor with Ticagrelor alone (2 arms). Started Nov 2020; status: completed.
02
Drugs
cangrelorticagrelor
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2020-003621-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003621-36.